Direct-acting antiviral agents (DAAs) are safe and effective in patients with hepatitis C. Conflicting data were reported on the risk of Hepatocellular carcinoma (HCC) during/after therapy with DAAs. Aim of this study was to evaluate incidence of newly diagnosed hepatocellular carcinoma and associated risk factors in patients with advanced hepatitis C treated with DAAs.

Newly diagnosed Hepatocellular Carcinoma in patients with advanced hepatitis C treated with DAAs: a prospective population study

Romano, Antonietta;Angeli, Paolo;Piovesan, Sara;Noventa, Franco;ANASTASSOPOULOS, GEORGIOS;Chemello, Liliana;Cavalletto, Luisa;Gambato, Martina;Russo, Francesco Paolo;Burra, Patrizia;CARLOTTO, ANTONIO;Alberti, Alfredo
2018

Abstract

Direct-acting antiviral agents (DAAs) are safe and effective in patients with hepatitis C. Conflicting data were reported on the risk of Hepatocellular carcinoma (HCC) during/after therapy with DAAs. Aim of this study was to evaluate incidence of newly diagnosed hepatocellular carcinoma and associated risk factors in patients with advanced hepatitis C treated with DAAs.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11577/3266560
Citazioni
  • ???jsp.display-item.citation.pmc??? 50
  • Scopus 87
  • ???jsp.display-item.citation.isi??? 91
social impact